Condition
Metastatic Paranasal Sinus Squamous Cell Carcinoma
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT06662058Not ApplicableRecruiting
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
NCT06636734Phase 2Recruiting
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Showing all 2 trials